SEFA 6131
Alternative Names: SEFA-6131Latest Information Update: 10 Jan 2022
At a glance
- Originator Pronova BioPharma
- Developer NorthSea Therapeutics
- Class Antihyperlipidaemics; Omega 3 fatty acids; Unsaturated fatty acids
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Hyperlipoproteinaemia type I
Most Recent Events
- 01 Dec 2021 Preclinical trials in Hyperlipoproteinaemia type I in Netherlands (PO) (NorthSea Therapeutics pipeline, December 2021)